On July 19, Innotek (688253.SH) opened the subscription, the issue price was 26.06 yuan per share, the subscription limit was 8,500 shares, and the price-earnings ratio was 32.65 times. It belongs to the Shanghai Stock Exchange Science and Technology Innovation Board, and Huatai United Securities is its sole sponsor.
Innotek is a high-tech biopharmaceutical enterprise focusing on the R&D, production and sales of POCT rapid diagnostic products. Compared with traditional laboratory testing products, the products have the advantages of low cost of use, convenient operation, fast inspection, and low requirements for supporting instruments and operators. Features. The company is rooted in the field of POCT rapid detection, featuring the detection of respiratory pathogens and the joint detection of multiple pathogens. With emergency outpatient clinics, especially children’s emergency outpatient clinics, as the entry point, the company is committed to building a leading brand of rapid joint detection of respiratory pathogens in China.
After the outbreak of the new coronavirus pneumonia in early 2020, the company responded quickly, coordinated the integrated operations of multiple departments within the company, and carried out research and development of new coronavirus detection products relying on the technical accumulation in the field of respiratory pathogen detection and genetic recombinant protein engineering. Over a short period of time, many technical difficulties were overcome, and on February 22, 2020, it passed the emergency channel approval of the State Food and Drug Administration, and obtained the first batch of registration certificates for new coronavirus IgM/IgG antibody detection kits in China, and subsequently participated in 3 projects. The formulation of the national standard for the new coronavirus antibody detection kit, followed by obtaining a number of overseas market access licenses, including the FDA’s EUA authorization, to support the global fight against the epidemic. Manufacturer of in vitro diagnostic reagents “National Advanced Group in Fighting against the New Coronary Pneumonia Epidemic”.
In addition, the company’s domestic new crown antigen detection products have obtained the registration certificate on March 29, 2022, and the company’s new crown antigen detection products for professional institutions and home self-test use have obtained EU CE certification and market access in many countries. With the continuous advancement of the new crown vaccination, the company has developed the “new coronavirus (2019-nCoV) neutralizing antibody detection kit (colloidal gold method)”, “new coronavirus (2019-nCoV)” 2019-nCoV) neutralizing antibody detection kit (quantum dot fluorescence immunochromatography)”, “new coronavirus neutralizing antibody detection kit (chemiluminescence method)” three novel coronavirus neutralizing antibody detection reagents, and has obtained CE Certification (self-declaration).
The prospectus disclosed that during the reporting period, the company’s new crown detection products were mainly antibody detection products and antigen detection products. In 2020, the company’s sales of new crown detection products were 917.0038 million yuan, accounting for 88.42% of the main business income in 2020. Since the second half of 2020, the company’s new crown detection product sales revenue has declined. The details are as follows:
The company attaches great importance to research and development. After years of development, it has built 6 technology platforms: immunochromatography platform, indirect immunofluorescence platform, liquid phase immunology platform, nucleic acid molecule detection platform, gene recombinant protein engineering platform, and cell and pathogen culture platform. Carry out professional division of labor to enhance the breadth and depth of research and development. The company carries out a number of research projects at the same time, which form a good complement to the existing products, and provide guarantee for the company’s continuous launch of new products and optimization of product structure in the future. As of the signing date of this prospectus, the company has obtained 16 invention patents and has 71 medical device product registration/filing certificates, including 56 three types of medical device registration certificates.
In 2019, 2020 and 2021, Innotek’s operating income was approximately RMB 138 million, RMB 1.037 billion and RMB 327 million, respectively; during the same period, R&D investment accounted for 15.47%, 5.73% and 9.52% of operating income, respectively.
Massive information, accurate interpretation, all in Sina Finance APP